Thrombolytic treatment of acute myocardial infarction;Trombolytisk behandling ved akutt hjerteinfarkt

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 5, 1998, Pages 692-695

  Schei, Morten A ^a   Hessen, Jens Olav ^a   Kildahl Andersen, Odd ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b Harstad Sykehus   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; TIME;

ADULT; AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0032548549     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 100 000 patients. Lancet 1994; 343: 311-22.
2. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarco miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401.
3. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarco miocardico. (GISSI-2): a factorial randomised trial of alteplase versus streptokinase and heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
5. ISIS-3 (Third International Study of Infarct Survival). ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
6. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-7.
7. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996; 312: 1637-41.
8. Birkhead JS. Time delay in provision of thrombolytic treatment in six district hospitals. BMJ 1992; 305: 445-8.
9. Reikvam Å. Bruk av trombolytika og andre medikamenter ved akutt hjerteinfarkt. Tidsskr Nor Lægeforen 1996; 116: 1671-4.
10. Reikvam Å for European Secondary Prevention Study Group. Pasientkarakteristika og mortalitet ved akutt hjerteinfarkt. Tidsskr Nor Lægeforen 1996; 116: 1668-70.
11. Abbasi I, Mortensen J, Visnes M, Gravseth HM. To års retrospektiv undersøkelse av pasienter med akutt hjerteinfarkt i et norsk fylkessykehus. Tidsskr Nor Lægeforen 1996; 116: 604-6.
12. Aursnes I, Osnes J-B, Platou ES, Smiseth OA, Amlie JP. Medikamentell behandling av akutt koronarsyndrom. Tidsskr Nor Lægeforen 1990; 110: 2788-90.
13. Norris RM, Roy S, Dixon GF. What proportion of patients with acute myocardial infarction should receive thrombolytic therapy? Br Heart J 1994; 71: 40.
14. Rawles JM. Risk-benefit analysis of thrombolytic therapy for acute myocardial infarction: a perspective. Coron Artery Dis 1992; 3: 1153-61.
15. Hannaford PC, Kay CR, Ferry S. Agism as an explanation for sexism in provision of thrombolysis. BMJ 1994; 309: 573.
16. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA 1996; 275: 777-82.
17. Goldberg RJ, Gorak EJ, Yarzebski J, Hosmer DW jr., Dalen P, Gore JM et al. A community-wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. Circulation 1993; 87: 1947-53.
18. Bleeker JK, Kruyssen HACM, Simoons ML, Lamers LM, Erdman RAM, Van der Does E et al. Patient and doctor delay in acute myocardial infarction: a study in Rotterdam, the Netherlands. Br J Gen Pract 1995; 45: 181-4.
19. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-5.
20. Lossius HM, Wisborg T, Gunnarson E, Høybjør S. Prehospital trombolytisk behandling av hjerteinfarkt i Nord-Norge. Tidsskr Nor Lægeforen 1995; 115: 1961-3.
21. The Heart and Stroke Foundation of Canada, the Canadian Cardiovascular society and the Canadian Association of Emergency Physicians, for the Emergency Cardiac Care Coalition. Recommendations for ensuring early thrombolytic therapy for acute myocardial infarction. Can Med Assoc J 1996; 154: 483-7.
22. MacCallum AG, Stafford PJ, Jones C, Vincent R, Perez-Avila C, Chamberlain DA. Reduction in hospital time to thrombolytic therapy by audit of policy guidelines. Eur Heart J 1990; 11 (suppl F): 48-52.